132 related articles for article (PubMed ID: 37882575)
1. Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
Alkader MS; Altaha RZ; Jabali EH; Attieh OA; Matalqa AW
Rom J Intern Med; 2024 Mar; 62(1):33-43. PubMed ID: 37882575
[TBL] [Abstract][Full Text] [Related]
2. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
5. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
6. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
[TBL] [Abstract][Full Text] [Related]
7. Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.
Xiao LS; Li QM; Hu CY; Cui H; Hong C; Huang CY; Li RN; Dong ZY; Zhu HB; Liu L
Ann Palliat Med; 2021 Nov; 10(11):11244-11254. PubMed ID: 34670386
[TBL] [Abstract][Full Text] [Related]
8. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
9. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
10. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease.
Yildirim HC; Guven DC; Aktepe OH; Taban H; Yilmaz F; Yasar S; Aksoy S; Erman M; Kilickap S; Yalcin S
J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079101
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.
Alkader M; Altaha R; Alkhatib L; Jabali EH; Alsoreeky MS
Cureus; 2022 Oct; 14(10):e30194. PubMed ID: 36381823
[TBL] [Abstract][Full Text] [Related]
12. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression after immunotherapy.
Abbas W; Rao RR; Popli S
South Asian J Cancer; 2019; 8(4):244-246. PubMed ID: 31807489
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
Chen S; Han L; Guo S; Tan Z; Dai G
Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment.
Kim J; Kim T; Jang TW; Kang H; Kim MH; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Han JY; Kang EJ
Thorac Cancer; 2022 Aug; 13(15):2170-2179. PubMed ID: 35785522
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).
Economopoulou P; Anastasiou M; Papaxoinis G; Spathas N; Spathis A; Oikonomopoulos N; Kotsantis I; Tsavaris O; Gkotzamanidou M; Gavrielatou N; Vagia E; Kyrodimos E; Gagari E; Giotakis E; Delides A; Psyrri A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466719
[No Abstract] [Full Text] [Related]
20. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]